Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-related Intracranial Hemorrhage: a Review of the Literature

Overview

Journal Neurocrit Care

Specialty Critical Care

Date 2009 Dec 8

PMID 19967567

Citations 25

Authors

Eric M Bershad

Jose I Suarez

Affiliations

Soon will be listed here.

Abstract

Warfarin-related intracranial hemorrhage carries a high mortality and poor neurological outcome. Rapid reversal of coagulopathy is a cornerstone of medical therapy to halt bleeding progression; however the optimal approach remains undefined. Prothrombin complex concentrates have promising features that may rapidly reverse coagulopathy, but remain relatively unstudied. We aim to review the literature regarding the use of prothrombin complex concentrates in patients with warfarin-related intracranial hemorrhage. A comprehensive review of the literature was conducted using PUBMED and Google Scholar databases to identify the use of PCC in patients with warfarin-related intracranial hemorrhage. The characteristics abstracted included the type of PCC, dosing, study design, type of intracranial hemorrhage, changes in the INR, and adverse effects. Prothrombin complex concentrates are heterogeneous in regards to factor concentration. PCC consistently reversed the INR in patients with intracranial hemorrhage. There is some evidence that PCC may reverse the INR more rapidly compared to fresh frozen plasma. Serious adverse effects were uncommon and included mainly thromboembolism. PCC has features which make it a promising therapy for patients with warfarin-related intracranial hemorrhage, and deserves more rigorous study in prospective-randomized controlled trials.

Citing Articles

Nutrition in children with exocrine pancreatic insufficiency.

Zheng Y, Mostamand S Front Pediatr. 2023; 11:943649.

PMID: 37215591 PMC: 10196508. DOI: 10.3389/fped.2023.943649.

Risk of Ischemic Stroke in Patients With Atrial Fibrillation After Extracranial Hemorrhage.

Zhou E, Lord A, Boehme A, Henninger N, de Havenon A, Vahidy F Stroke. 2020; 51(12):3592-3599.

PMID: 33028172 PMC: 7751804. DOI: 10.1161/STROKEAHA.120.029959.

Emergency Reversal of Anticoagulation.

Yee J, Kaide C West J Emerg Med. 2019; 20(5):770-783.

PMID: 31539334 PMC: 6754204. DOI: 10.5811/westjem.2018.5.38235.

Critical care neurology: Five new things.

Wijdicks E, Rabinstein A Neurol Clin Pract. 2018; 1(1):34-40.

PMID: 29443309 PMC: 5766174. DOI: 10.1212/CPJ.0b013e31823c85c2.

Pharmacotherapy Pearls for Emergency Neurological Life Support.

Brophy G, Human T Neurocrit Care. 2017; 27(Suppl 1):51-73.

PMID: 28913813 DOI: 10.1007/s12028-017-0456-x.

References

Steiner T, Rosand J, Diringer M . Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2005; 37(1):256-62. DOI: 10.1161/01.STR.0000196989.09900.f8. View

Josic D, Hoffer L, Buchacher A, Schwinn H, Frenzel W, Biesert L . Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res. 2001; 100(5):433-41. DOI: 10.1016/s0049-3848(00)00339-x. View

Roddie P, Stirling C, Mayne E, Ludlam C . Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost. 1999; 81(4):667. View

Pereira S, Rowbotham D, Fitt S, Shearer M, Wendon J, Williams R . Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005; 42(3):365-70. DOI: 10.1016/j.jhep.2004.11.030. View

White 2nd G, Roberts H, Kingdon H, Lundblad R . Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood. 1977; 49(2):159-70. View

Evans G, Luddington R, Baglin T . Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2002; 115(4):998-1001. DOI: 10.1046/j.1365-2141.2001.03214.x. View

Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G . Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 1995; 73(4):675-9. View

Nee R, Doppenschmidt D, Donovan D, Andrews T . Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999; 83(2):286-8, A6-7. DOI: 10.1016/s0002-9149(98)00842-x. View

Makris M, Greaves M, Phillips W, Kitchen S, Rosendaal F, Preston E . Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997; 77(3):477-80. View

10.

Hampton K, Preston F, Lowe G, Walker I, Sampson B . Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol. 1993; 84(2):279-84. DOI: 10.1111/j.1365-2141.1993.tb03065.x. View

11.

Giles A, Nesheim M, Hoogendoorn H, Tracy P, Mann K . The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. Blood. 1982; 59(2):401-7. View

12.

Seitz R, Dodt J . Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999; 95(4 Suppl 1):S19-23. DOI: 10.1016/s0049-3848(99)00080-8. View

13.

Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V . Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004; 113(6):371-8. DOI: 10.1016/j.thromres.2004.04.004. View

14.

McQuillan A, Eikelboom J, Hankey G, Baker R, Thom J, Staton J . Protein Z in ischemic stroke and its etiologic subtypes. Stroke. 2003; 34(10):2415-9. DOI: 10.1161/01.STR.0000092124.52084.4B. View

15.

Francis C, Berkowitz S, Comp P, Lieberman J, Ginsberg J, Paiement G . Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003; 349(18):1703-12. DOI: 10.1056/NEJMoa035162. View

16.

Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I . Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007; 98(4):790-7. View

17.

Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G . A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg. 2008; 74(9):858-61. View

18.

Aledort L . Factor IX and thrombosis. Scand J Haematol Suppl. 1977; 30:40-2. DOI: 10.1111/j.1600-0609.1977.tb01516.x. View

19.

Flibotte J, Hagan N, ODonnell J, Greenberg S, Rosand J . Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004; 63(6):1059-64. DOI: 10.1212/01.wnl.0000138428.40673.83. View

20.

TULLIS J, Melin M . Management of Christmas disease and Stuart-Prower deficiency with a prothrombin-complex concentrate (factors II, VII, IX, X). Bibl Haematol. 1968; 29:1134-9. DOI: 10.1159/000384751. View